Chemotherapy in Advanced Pancreatic Cancer
Author Information
Author(s): Sultana A, Tudur Smith C, Cunningham D, Starling N, Neoptolemos J P, Ghaneh P
Primary Institution: CRUK Liverpool Cancer Trials Unit, Cancer Research Centre
Hypothesis
Does chemotherapy provide a significant survival advantage in advanced pancreatic cancer compared to best supportive care?
Conclusion
Gemcitabine-based combinations improve progression-free survival and response rates compared to 5FU alone, but come with greater toxicity.
Supporting Evidence
- Gemcitabine combinations showed significantly better progression-free survival compared to 5FU alone.
- 5FU combinations did not show a significant advantage over 5FU alone for time to progression.
- Greater toxicity was observed with gemcitabine-based combinations.
Takeaway
This study found that using a combination of chemotherapy drugs can help people with advanced pancreatic cancer live longer, but it can also cause more side effects.
Methodology
A systematic review using Cochrane methodology to evaluate secondary outcome measures for chemotherapy in advanced pancreatic cancer.
Potential Biases
Evidence of potential publication bias was noted.
Limitations
Quality of life assessments were not included due to varying reporting methods.
Participant Demographics
Patients with advanced pancreatic cancer, including those with metastatic disease.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI=0.70–0.88
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website